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AIM OF THE STUDY 
Early detection of heterotopic ossification in spinal cord injury patients through biomarkers. 
 
 
OBJECTIVES OF THE STUDY 
 
1. To evaluate the sensitivity and specificity of CPK in early detection of heterotopic 
ossification in spinal cord injury patients. 
2. To evaluate the sensitivity and specificity of osteocalcin in early detection of 
heterotopic ossification in spinal cord injury patients. 
3. To compare serum CPK, osteocalcin levels in early detection of heterotopic 
ossification following spinal cord injury. 
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INTRODUCTION 
Spinal cord injury (SCI) is a partial or total disruption of the structural or functional integrity of 
the spinal cord following non-traumatic or traumatic cause leads to temporary or permanent 
impairment of motor, sensory and/or autonomic functions. 
The spinal cord functions mainly in the transmission of neural signals between the brain and the 
target organs in the body but also contains neural circuits that can independently control 
numerous reflexes and central pattern generators. The disruption of these neurohumoral 
functions following spinal cord injury results in various acute and chronic secondary 
complications. There is a wide range of short and long term complications like Heterotopic 
Ossifications, spasticity, deep venous thrombosis, osteoporosis etc. 
Heterotopic ossification (HO) is defined as ‘formation of mature, lamellar bone in non-osseous 
tissue, usually between the muscle and the joint capsule’. This happens as a consequence of 
various conditions and trauma. These include neurological injuries like spinal cord injury, 
traumatic brain injury, post surgical intervention at the particular joint and direct injury to the 
muscle. 
The exact cause of HO is not clear till date though the research has been well advanced in this 
field. The widely accepted concept is transformation of primitive mesenchymal cells which are 
present in the connective tissue into bone forming cells called osteoblasts when exposed to 
certain inducing agents(1). The exact sequence of events that lead to ectopic bone formation, the 
proper etiology and predisposing factors are still under exploration. 
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Early identification of this particular condition has always been a challenge. As the condition 
develops over a period of time with non specific complaints at the local site and occasionally 
mild constitutional symptoms; clinical suspicion needs to be tailored with proper investigation to 
achieve diagnosis at the earliest. It is well established that the medical treatment is most effective 
only when the patient receives it before the radiological evidence of bone formation. There are 
various laboratory biomarkers like alkaline phosphatase(ALP), creatine phosphokinase, 
osteocalcin and radiological tools including the use of ultra sound examination in early detection 
of HO have been reported in the literature. Three phase bone scan is widely accepted as Gold 
standard(2–4). 
Currently pharmacotherapy is the mainstay of treatment for HO. Disodium Etidronate 
(Didronel), a non nitrogenous bisphosphonate was the drug of choice for both prophylaxis and 
treatment as it can slow down the mineralization process(5). Didronel is expected to be effective 
in early stage of the disease(3). Other medications like NSAIDs, Warfarin(6,7), glucocorticoids 
are also in use. Indomethacin is used most commonly which is shown to be effective in the 
prevention of HO especially when the patient receives during the first two months after the 
spinal cord injury even before the clinical features appear(8–10). Low field irradiation showed 
some response when used as the primary treatment once first clinical signs were observed(11–
13). The surgical intervention is the last resort available when the HO becomes fully mature. The 
complication rate is high for the surgical resection which includes increased bleeding and 
recurrence.  
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JUSTIFICATION OF THE STUDY 
HO is one of the complications following spinal cord injury. The precise mechanism of HO 
formation is not known. HO forms in the muscle planes primarily rather than muscle itself.  
Though the muscle fibers are not involved in the process of HO formation, they are incorporated 
in to the newly formed bone tissue or compressed by the adjacent fibrosing soft tissue 
calcification that leads to necrosis of the local muscle(14). 
 
In spinal cord-injured patients the incidence of HO is between 20% and 25%(15). Increased joint 
stiffness, a limited range of motion, warmth, swelling and erythema are the main clinical signs of 
HO. The gold standard for the diagnosis of heterotopic ossification is three-phase bone 
scintigraphy. It is the most sensitive imaging technique for the early detection of HO. In the 
untreated patient the three-phase bone scan detects the formation of HO generally 4 to 6 weeks 
before ossification is noticed on the X-ray study. The serial three-phase bone scan can also be 
used as a reliable method of determining the maturity of HO(4). 
 
Ultrasonography was also proved to be detecting the condition of HO sooner than the 
conventional radiography(16–18). Local ultrasonographic signs of inflammation like “zone 
phenomenon” and cystic changes in spinal cord injured patients are suggestive of heterotopic 
ossification. Snoecx et al demonstrated possible relationship between microtraumatic lesion and 
occurrence of HO by ultrasonographic changes(17). In a study done on patients with HO after 
total hip replacement, it was found that ultrasonography is also the probable investigative choice 
not only for the early identification of the condition, but also for the follow-up of HO(16). But 
the expertise makes the usage of sonography more difficult. 
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The primary investigations include the assessment of ALP levels and bone scintigraphy. The 
sensitivity of serum alkaline phosphatase which is elevating as an indicator of heterotopic bone 
has been a matter of disagreement in the literature (16–18). Scintigraphic demonstration of 
heterotopic bone can happen when the serum ALP is within normal limits though the levels of 
the same are rising pace below the upper limit(19). After Four weeks of injury alkaline 
phosphatase levels may reach up to 3.5 times the normal value, with a peak concentration around 
the 12th week. If HO formation is small, ALP levels may remain unchanged. This is a good 
parameter in the absence of fractures. An increase may indicate the functional transformation of 
mesenchymal stem cells into chondrocytes(15). Kluger et al showed in children there is no ALP 
increase during the development of heterotopic ossification(20). 
 
Serum creatine phosphokinase (CPK/CK) is a marker of muscle injury. There are 3 iso-enzymes, 
described in the literature with the predominance of existence in muscle as CK-MM, CK-BB in 
brain and CK MB in heart muscle. The normal serum contains CPK MM activity 95-100% of the 
total CK. Hence it is legitimate to measure the CPK activity. The peak period for the rise in CPK 
level is 24hrs post injury(21). Singh RS and Sherman et al showed an elevation of serum CPK  
may be a more reliable subsequent HO predictor(22,23). Both these studies showed CPK as a 
potential predictive test for HO but they lack good study qualities such as inadequate sample size 
and low correlation with the people who developed HO. Hence CPK is included in the current 
proposed study. 
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Serum osteocalcin is released from the osteoblasts during the bone formation stage. In 1993, 
Mysiw WJ et al showed this biomarker may not contribute for the diagnosis of neurogenic 
heterotopic ossification once the clinical diagnosis has been established(24). But this study has 
done only on 12 traumatic brain injury patients and as there is significant improvement in the 
standard operating procedures of serum osteocalcin assay over past two decades, it is also 
included in the current study for the spinal cord injury population group. 
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REVIEW OF LITERATURE 
Heterotopic ossification (HO) is one of the non life threatening complications following spinal 
cord injury which causes functional limitation. HO is described by Dejerine and Ceillier in 1918 
as paraosteo arthropathy. It is defined as the formation of lamellar bone in periarticular non 
ossified soft tissue but without periosteal involvement(15,25). This bone has collagen which is 
arranged in regular parallel alignment of sheets which becomes mechanically strong eventually. 
Based upon the origin of ectopic bone, location, clinical presentation, isolated or associated with 
other conditions and progressive occurrence the condition of HO has been classified into 4 types, 
they are 
(a) Post traumatic (following bone fracture, direct muscle trauma and surgical trauma). 
(b) Neurogenic spinal cord injury, traumatic brain injury and very rarely in non traumatic 
CNS injury like stroke and Guillian- Barré syndrome. 
(c) Myositis. 
(d) Progressive fibro dysplasia ossificans.  
Incidence   
The range of the incidences of spinal cord injury in Asia was between 12.06 and 61.6 per million 
population. The incidence of traumatic spinal cord injury was lower than that in North America 
due to socioeconomic development. In all the countries the highest incidences were reported in 
people who were between 20 and 50 years. In Asia alone, majority of the adults with the range 
between 26.8 and 56.6 years are afflicted with the sequelae of spinal cord injury, due to their 
capability of being most dynamic and productive members of the society(26). 
12 
  
Incidence of HO, depending on the study and various institutions ranges from 20 to 30%(15,27). 
This discrepancy is also due to several other factors such as population studied, duration of the 
studies, the methods used for data collection and procedures adopted in different centers. 
Clinically significant heterotopic ossification usually develops in about 20% of patients with 
spinal cord injury. Out of these patients with HO, 8 to 10 percent develop severe functional 
limitations.  Joint ankylosis was noticed only in 3 to 5 % of all these patients with HO in spinal 
cord injury(28,29). A correlation with age is suggested with heterotopic ossification being more 
common in patients between 20 to 30 years old. Although this may be related to the range of age 
at which spinal cord injury are most frequent. The incidence of HO in children with spinal cord 
injury was 3-10% and it was noticed that the spontaneous regression of HO happens more 
commonly in children and young adults(20,30). 
Etiology and pattern of formation of HO 
HO always occurs below the neurological level in the spinal cord injury(28,31). The increased 
spasticity may be seen associated with HO formation. But the causation of HO due to  spasticity 
is still unknown(32). It has been strongly correlated with the degree of completeness of spinal 
cord injury and the direct trauma to the muscle(33). The association of HO formation and the 
spinal cord injury at cervical and thoracic level is more established than the occurrence of the 
same in the lumbar cord injuries(34,35). 97% of the HO happens in hip joint following spinal 
cord injury(29). In the hip joint the ossification of the tissues happens most commonly in the 
medial side extending from the symphysis pubis to the anteromedial aspect of the femoral shaft. 
Occasionally HO can even form posterior to the femoral neurovascular structures. In mature HO 
of hip joint it is also seen in anterior aspect involving iliopsoas with advancing lateral and 
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involving gluteus minimus posteriorly extending from ileum to encase the sciatic nerve(2). In 
knee joint HO, though very rare it happens anteriorly beneath the quadriceps muscle medially in 
the medial collateral ligament, posteriorly about the insertion of hamstring muscles.  
Other joints that are involved in HO formation in the decreasing incidence are knee, elbow, 
shoulder, hand and spine. 
A recent case control study of 264 patients by Citak et al showed there is a higher risk of 
developing HO in spinal cord injury patients with spasticity, thoracic trauma, pneumonia, urinary 
tract infection and presence of tracheostomy along with completeness of injury(36).  
The influence of passive range of exercises on the risk of heterotopic ossification is so far 
unclear. But the role of micro trauma, mechanical stress to the muscles and the tendons appears 
to influence the bone formation. These may arise either from vigorous passive exercises or 
immobilization and the muscle imbalance causing the increased pressure on the soft tissue. This 
mechanical stress causes local micro trauma that may induce the bone formation. Michelson J. E. 
et al in a rabbit study showed increased duration of immobilization of the animal correlates the 
grade of HO where as five weeks of vigorous mobilization resulted in little or no HO 
formation(37). 
In a recently done study by Christina et al to see the role of increased paratharmone levels in the 
formation of HO, a 12 fold increased ALP activity when BMP levels increased due to trauma or 
immobilization, proved hyperparathyroidism increases the risk of HO formation(38). 
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Race of the patient does not appear to be a significant factor for heterotopic ossification that 
occurs following spinal cord injury. A study done in 1992 about the sex predilection showed 
male spinal cord injury patients are twice as likely to develop HO as are female spinal cord 
injury patients(39). But a recent study showed there is no known sex predilection for neurogenic 
heterotopic ossification(5).  
Pathophysiology 
The formation of ectopic bone is similar to callus formation but it happens in the connective 
tissue between muscle planes. It is usually in the contiguity of the skeleton without periosteal 
involvement. Although the precise mechanism for the heterotopic ossification is largely 
unknown, there are few humoral, neural and local factors probably play a role in the 
pathophysiology(2). As the HO begins to form, the blood flow to the particular affected soft 
tissue will be increased along with the inflammatory reaction(40). The condition advances with 
cellular infiltration, fibroblastic proliferation, osteoid formation and deposition of bony matrix in 
a sequence. Ackerman noticed zone phenomenon during the maturation of new bone that occurs 
from outside to inside of the three zones. These three zones are thin outer zone of previously 
formed bone with well demarcated outer trabecular rim, intermediate zone with immature bone 
lined by osteoblasts and inner zone with undifferentiated fibroblasts studded in necrosed muscle 
tissue(41). Progressive mineralization happens at the junction between the outer and the 
intermediate zones which will eventually become radiologically opaque. The mature HO 
comprises of cancellous bone with Haversian canals, blood vessels, bone marrow and cortex. 
There are few histopathological studies that showed a minor amount of hematopoesis happening 
in this mature bone(28,40). 
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Chalmers(42) has proposed the existence of three conditions which are required for the HO 
formation. They are  
(a) Presence of bone forming precursor cells which are primitive mesenchymal cells.  
(b) A stimulus or an inducing agent that has been recently identified as bone morphogenic 
protein (BMP). 
(c) The environment that permits osteogenesis.  
Urist explored the role of BMP in 1997. He observed that the bone matrix which is 
demineralised can initiate new bone formation when supplied with BMP in non ossified 
tissue(43). The BMP is released from healthy bone tissue in the settings of inflammation, 
immobilization, trauma and venous stasis(38). There are various types of BMPs that are essential 
for the differentiation of mesenchymal cells into osteogenic cells of which BMP4 is 
important(15,44). Usually in normal conditions this BMP is under the action of antagonists such 
as gremlin, noggin, chordin and follistatin. The over expression of BMP4 happens with the 
decreased inhibitory response of these substances thus causing increase in the number of 
osteogenic cells(15). 
There are mainly two factors that are responsible for ectopic ossification at cellular and 
molecular level (a) ischemic degeneration of involved muscles and (b) presence of BMPs. The 
sources of these BMPs in the muscle are mesenchymal cells and endothelial cells. This BMPs act 
upon the target cells which are mesenchymal cells and the smooth muscle cells. There is tenfold 
increase in the ALP activity when these multipotent mesenchymal stromal cells were stimulated 
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by BMP which can eventually become preosteoblastic cells(45). Canalis noticed there is only 
five fold ALP activity when BMP stimulated the mature osteoblastic cell. In his study he also 
observed BMP2 generally exhibits more expression than that of BMP3 which causes more 
increased ALP activity. In fact BMP 3 causes inhibition of osteogenesis(47). 
In the early stage of HO formation, there are reported venous stasis, arterio-venous shunting and 
ischemic damage that cause the release of eicosanoids which are important factors in bone 
metabolism(15). There are many such inducing agents like insulin like growth factor II, tissue 
growth factor β, platelet-derived growth factor interleukin-1 and interleukin-6 which were 
observed in rat experiments. And these were shown to increase the osteoblastic activity in the 
animals with spinal cord injury. A 24 hour urine sample for PGE2 excretion and hydroxyprolein 
in spinal cord injured patients have a valuable indication for the early HO(48). 
 Medici and Olsen brought up a new concept of endothelial mesenchymal transition (EndMT) in 
which there is a dedifferentiation of cells from the vascular endothelium to a stem cell phenotype 
that eventually forms the bone, fat and cartilage. They proposed that these vascular endothelial 
cells are the primary factors for the cellular origin of HO. The vascular endothelial growth factor 
and several other EndMT- inducing transcription factors may serve as possible agents to arrest 
the HO formation and could be involved in the further therapeutic interventional studies(38,49).  
Dejerine suggested the intermedio-lateral sympathetic columns of the damaged spinal cord cause 
the neurogenic heterotopic ossification through the autonomic dysregulation(28,50). Hohmann in 
1986 in his study, found that bones along with periosteum are innervated by sympathetic 
vasoactive intestinal peptide (VIP) containing nerve fibers(51).  Though the relationship between 
the bone formation and the nervous system is unclear it is well established that specific 
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neurotransmitters have a direct effect on bone metabolism. Other neurotransmitters like 
glutamate, substance P, calcitonin gene related protein and catecholamines also showed to 
increase the osteoblastic activity  and at the same time reducing the osteoclastic activity(2). In 
another study, patients with brain injury and polytrauma produced more bony callus in the 
fracture site as part of healing than their counter part patients who did not have traumatic brain 
injury. The increased  levels of catecholamine and sympathetic activity and the increased 
calcitonin may be the cause for more rapid healing of fractures(52–55). 
Recent rat spinal cord injury models showed leptin, a hormone which plays important role in the 
regulation of energy homeostasis influences the bone formation by possible process of 
hypothalamus and sympathetic nervous system(56,57). 
Histology 
It is difficult to differentiate the heterotopic ossification from callus formation of a healing 
fracture histologically. The initiation of the ossification process is fibroblastic proliferation. The 
studies of histological aspects demonstrated a zone of fibroblastic metaplasia followed by 
chondroblast which subsequently transformed into osteoblast cells with blood vessels and 
Haversian system. 
In the ectopic bone, mature lamellar bone is seen peripherally surrounded by compressed muscle 
fibers and connective tissue that form a capsule. Around the HO edema, muscle necrosis and 
osteoporosis with signs of hypersensitivity are also noted. These are considered to be 
consequences rather than cause of HO. Histological studies showed bone forms in connective 
tissue between muscle planes and not in the actual muscle itself(15). The histological picture of 
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the mature HO may depict cancellous bone, mature lamellar bone with blood vessels and bone 
marrow with demonstration of minute levels of haematopoiesis. In a study done by Lotta et al to 
describe the ultra structural and histological features of soft tissue and skin near the HO that 
formed in two spinal cord injury patients, showed there are changes in the endothelial cells and 
basement membrane of capillaries and small vessels. The endothelial cells showed hyperactivity 
whereas basement membrane showed thickness and reduplication. They concluded these 
vascular alterations may induce hypoxemic changes in the tissues around the joint that lead to 
metabolic changes which can lead to the development of HO(58). 
There are few main histological stages in the usual evolution of HO following trauma which are 
described as follows 
 (a) Spindle cell formation that happens within the first week of trauma, 
 (b) Primitive osteoid stage that develops in 7 to 14 days 
(c) Primitive cartilage and woven bone stage that can be seen in the second week,  
(d) Trabecular bone formation at 2 to 5 weeks,  
(e) Zone phenomenon which is immature, undifferentiated central tissues with mature 
peripherally located lamellar bone that happens approximately at 6 weeks.  
(f) Mineralization in which hydroxyapatite crystals is formed by replacing the amorphous 
calcium phosphate. (59) 
19 
  
 (g) True bone formation that happens over a period of approximately 6-18 months. This happens 
only in the muscle planes, not within the muscle without disrupting the joint capsule. It may 
attach to the adjacent bone cortex with or without damaging the same. 
Clinical features 
It is often difficult to diagnose heterotopic ossification in its initial stage. The symptoms and 
signs may appear as early as 3 weeks to 12 weeks after the injury. The earliest symptom of 
heterotopic ossification is usually stiffness and restriction of joint movements which progresses 
gradually. This is usually accompanied by swelling which eventually becomes indurated, with 
erythema, local rise of temperature, palpable mass and local pain (especially in the patients with 
incomplete spinal cord injury). It is not unusual to find contracture of the local muscles which 
can contribute for the further reduction of range of movements. Sometimes it is associated with 
mild to moderate grade fever.  As the HO matures the local manifestations will slowly regress 
and eventually a hard, non tender bony lesion may arise approximately six to twelve weeks after 
the initiation of symptoms at the particular joint. 
In children with spinal cord injury, decreased range of movement can be the only presentation 
without any other local symptoms and signs. In pediatric patients the average length of time 
reported between diagnosis of neurogenic heterotopic ossification and the spinal cord injury is 
around fourteen months whereas this duration in adult patients is six months(5). 
The most common site for HO formation following spinal cord injury is hip joint(28,29) and the 
muscles which tend to be involved more frequently are hip flexors and abductors than hip 
extensors and adductors. The non articular manifestations are rarely noticed. Cases of nerve 
20 
  
entrapment around the joint and also vascular compression which is venous predominantly were 
noted. HO with associated increased spasticity can cause the obstruction of lymphatic vessels 
manifesting the features of lymphedema. Large amounts of heterotopic ossification can cause 
skin break down, pressure ulcers and inability to sit upright thus affecting the functional abilities 
especially transfers and difficulty wheel chair mobility. 
The differential diagnosis of heterotopic ossification includes deep venous thrombosis (DVT), 
cellulites, septic arthritis, hematoma, osteomyelitis, tumor, fracture or local trauma. It is always 
difficult to differentiate clinically especially from lower extremity deep venous thrombosis 
because the same symptoms of swelling, erythema, pain can occur especially reason being 
immobilization as the causative factor for both conditions. Few studies showed DVT and 
heterotopic ossification have been associated positively,  this might be due to the pressure effect 
and local inflammation of the ectopic bone promote the adjacent thrombus formation by causing 
compression of the nearby veins and causing phlebitis(60–64).  
 Natural course of HO 
Most of the heterotopic ossification (around 80%) have relatively benign course leaving no 
complications. In the remaining 20% significant loss of motion develops with bony ankylosis. 
Among these, around 10% may cause severe disability eventually(3). It was noticed stabilized 
post traumatic HO, can spontaneously regress in few cases where as post SCI-HO usually does 
not regress without any surgical intervention(65). In 1999, a case of post burn heterotopic 
ossification transformation in to osteosarcoma was reported(66). 
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Diagnosis and classification of HO 
Most of the patients can be suspected to have HO by the above mentioned clinical 
manifestations. In these patients, there is a necessity for the radiography to see the extent of the 
involvement of a specific joint. There are various methods of staging of heterotopic ossification 
mentioned in the literature. X-ray has been the important tool to grade HO.  
Nicholas in 1973(67) proposed the staging of heterotopic ossification as shown in table 1 
Table 1. Nicholas Staging of heterotopic ossification 
Stage 1 Swelling, normal X- ray increased serum ALP  
Stage 2 Swelling, positive X- ray,  and increased serum ALP 
Stage 3 No swelling, positive X- ray and increased serum ALP 
Stage 4 No swelling, positive X- ray and normal serum ALP 
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In the same year 1973, Brooker et al (68) described heterotopic ossification classification around 
the hip joint following total hip replacement surgery on the basis of antero-posterior hip 
radiograph. 
Table 2. Brooker et al grading of HO 
Grade 0 No heterotopic ossification 
Grade 1 Diffuse islands of bone within the soft tissues about the hip 
Grade 2 Bone spurs with at least 1 cm gap in between the bony surfaces 
Grade 3 Bone spurs with less than 1cm between the bony surfaces  
Grade 4 Bony ankylosis of the hip joint 
A recently proposed classification by Mavrogenis et al (69) in 2012 depicts the anatomical 
location of ectopic bone, bony ankylosis and etiology of the neurological injury(traumatic spinal 
cord injury or traumatic brain injury). This helps in the pre operative planning for the surgical 
approach for the excision of the same. To an extent this method may also be useful for the 
estimation of the intra operative complications like blood loss and transfusion requirements. 
Nonetheless this classification in the study done failed to show the significant relationship 
between the HO type and recurrence rate of the same.  
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Type  with subtypes Description  
Type1  
a) Spinal cord injury 
b) Traumatic brain injury 
HO at the anterior aspect of the hip joint or 
proximal end of the femur; +/-  ankylosis 
Type 2   
a) Spinal cord injury 
b) Traumatic brain injury 
HO at the posterior aspect of the hip joint or 
proximal end of the femur; +/- ankylosis 
Type 3  
a) Spinal cord injury 
b) Traumatic brain injury 
HO at the anterior and medial aspect of the hip 
joint or proximal end of the femur; +/- 
ankylosis 
Type 4  
a) Spinal cord injury 
b) Traumatic brain injury 
HO at the circumferential aspect of the hip 
joint +/- ankylosis 
Table 3. classification by Mavrogenis et al (2012) 
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IMAGING STUDIES 
Radiography 
The plain radiographs detect HO as early as around one to ten weeks after the first clinical signs 
in the patients with spinal cord injury, which is relatively a late finding. The increased density of 
the soft tissues around the joint is the earliest radiographic sign of HO. As the condition 
advances the calcium precipitates are seen as flocculent densities (tufts of wool). The formation 
of bony cortex with the trabeculations delineating from the soft tissue can be seen in the 
advanced stages of HO. In a long term follow up study, X-ray modality failed to show the 
maturity of HO(70). It could be possible for the immature bone is masked by the mature bone 
substance. This technique may be valuable if they show modification in sequential studies(40). It 
also failed to detect the possible reoccurrence or reactivation(71).  
CT scan 
CT imaging is a tool for the better visualization of HO among the soft tissues compared to plain 
X-ray. Typical findings of this investigation include an enlarged muscle belly, low attenuation of 
soft tissue mass(72,73). Single-photon emission computed tomography (SPECT) and three 
dimensional tomography (3D-CT) are proved to be of much use in planning the surgical 
resection of HO. This can  avoid the immature bone being excised in order to prevent the 
recurrence(72). 
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MRI scan  
Magnetic resonance imaging (MRI) is usually not recommended for the diagnosis of heterotopic 
ossification. The features of HO on MRI are low signal intensity rim and a tumor like 
enlargement of involved soft tissues with high signal intensity(74,75). A high cost and low 
specificity in diagnosis of early stage of HO make the MRI modality less preferable in regular 
practice(15). 
Ultrasonography 
Ultrasonography can detect HO earlier than the conventional radiography(16–18). “Zone 
phenomenon” and cystic changes in patients with spinal cord injury are suggestive of heterotopic 
ossification. Snoecx et al described possible relationship between microtrauma and occurrence of 
HO by USG changes(17). Pistarini et al in 1995 conducted a study on patients with HO after 
total hip replacement to see the sonography diagnostic value. They observed Ultrasonography 
was found to be the probable investigation of choice for both the early identification of the 
condition and for the follow-up of HO(16). But the expertise makes the usage of sonography 
more difficult. Usually it is not practiced for the routine patient care. 
Triple phase bone scintigraphy  
The three phase bone scan is considered to be the gold standard for early detection of HO as it 
has highest sensitivity for the localization of the same(2). It becomes positive typically during 
the third week following the spinal cord injury which allows detecting the condition four to six 
weeks earlier to plain X-rays. A remarkable finding of the ability of bone scan in differentiating 
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the callus formation from normal bone in experimental fractures in 1971 made a rapid advance in 
the technology and science of bone scan(76). This study also concluded the reliability of bone 
scan in monitoring the maturity of HO.  
There are three phases during which the images are studied after the intravenous administration 
of radionuclide Technetium-99m. 
Phase I (Blood flow phase): Detects areas of increased blood flow, an early sign of 
inflammation. 
Phase II (Blood pool phase): Detects areas of increased static status; a phenomenon, several 
minutes after injection. 
Phase III (Static bone phase): Determines the degree of osseous uptake of the labeled 
radionuclide several hours after injection. 
First two phases are effective in detecting HO as early as 2.5 weeks after SCI followed by third 
phase around 1 week later. Rossier et al noticed the absence of vascularity as a sign of the 
maturity and may be planned for the surgical resection(40). 
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LABORATORY EVALUATION   
Alkaline Phosphatase 
The sensitivity of elevating serum alkaline phosphatase as an indicator of heterotopic bone has 
been a matter of disagreement in the literature (16–18). Scintigraphic demonstration of 
heterotopic bone can happen when the serum ALP is within normal limits though the levels of 
the same are rising pace below the upper limit(19). After Four weeks of injury alkaline 
phosphatase levels may reach up to 3.5 times the normal value, with a peak concentration around 
the 12th week. If HO formation is small, ALP levels may remain unchanged. This is a good 
parameter in the absence of fractures. An increase may indicate the functional transformation of 
mesenchymal stem cells into chondrocytes(15). Other major drawbacks of this investigation are 
normal levels do not correlate with the advanced stage of HO and peak level doesn’t represent 
the peak activity of osteoblasts. A non specific elevation of ALP can happen if patient sustains 
skeletal injuries, liver injuries or receives surgical treatment for the fractures. Kluger et al 
showed in children there is no ALP increase during the development of heterotopic 
ossification(20). 
 
Creatine Phosphokinase (CPK/CK) 
Serum CPK is an intracellular enzyme. The disruption of cell membranes due to injury or 
hypoxia causes the release of CK from the cell into systemic circulation. There are 3 iso-
enzymes, described in the literature with the predominance of existence in muscle as CK-MM , 
CK-BB in brain and CK MB in heart muscle.  
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CPK catalyzes the following reversible reaction by transferring phosphate group 
ADP + Creatine Phosphate  ATP + Creatinine  
 
The usual method of total CK measurement involves spectrometric determination of the rate of 
forward reaction. There are various modalities to separate CK into its isoenzymes like column 
chromatography, electrophoresis and radioimmunoassay of which electrophoresis is the most 
commonly used one in the clinical laboratories. The three isoenzymes behave as follows CK-
MM – neutral, CK-MB – intermediate and CK-BB – most mobile 
 
The normal serum contains CPK MM activity 95-100% of the total CK. The peak period for the 
rise in CPK level is 24hrs post injury(21). In the literature, CPK was well identified as a marker 
for muscle injury, induced muscle soreness due to vigorous exercises(21,77,78). Singh RS and 
Sherman et al showed an elevation of serum CPK  may be a more reliable subsequent HO 
predictor(22,23). Both these studies showed CPK as a potential predictive test for HO but they 
lack good study qualities such as inadequate sample size and low correlation with the people 
who developed HO.  
 
Osteocalcin 
Serum osteocalcin is a bone-specific, vitamin K dependent, calcium binding, non-collagen 
protein in the bone matrix. The molecular weight of osteocalcin is approximately 5800 Dalton. It 
consists of 49 amino acids. Osteocalcin is also called as “bone Gla protein” because of the 
presence of three γ-carboxyglutamic acid residues. Osteocalcin is released from the osteoblasts 
during the bone formation stage. Its production is stimulated by vitamin D3. Once released, part 
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of the osteocalcin is incorporated in the bone matrix and remaining is delivered into the blood 
stream. In the blood, both carboxylated and under-carboxylated osteocalcin are present(79). In 
vitro experiments on primary adipocytes and isolated islets by Lee NK et al, it was noticed that 
the uncarboxylated form of osteocalcin is active and the carboxylated form is inactive(80). 
Osteocalcin is widely used as a bone turnover marker, as its level in serum can be related to the 
rate of bone turnover in many bone metabolism disorders (osteoporosis, primary 
hyperparathyroidism, secondary hyperparathyroidism, Paget’s disease) especially in monitoring 
the therapeutic response. In blood, both intact osteocalcin (amino acids 1-49) and large N-Mid 
fragment (amino acids 1-43) are present. N-mid fragment resulting from cleavage is stable, 
whereas intact osteocalcin is unstable because of the protease cleavage between amino acids 43 
and 44. 
In 1993, Mysiw WJ et al showed this biomarker may not contribute for the diagnosis of 
neurogenic heterotopic ossification once the clinical diagnosis has been established. This study 
was conducted in traumatic brain injury patients(24).  
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MANAGEMENT 
 
Pharmacological intervention: 
NSAIDs: 
Indomethacin (a non- selective COX inhibitor) is the drug used mainly in the prevention of 
heterotopic ossification. It should be initiated within two months of injury and continued for four 
to six weeks. Long acting indomethacin 75mg daily or standard release indomethacin 25mg 
thrice daily is suggested(9). In a study performed by Banovac K et al in 2004, when Rofecoxib 
was used as a primary prevention with a dosage of 25mg daily for four weeks, there was a 
significant decrease in the incidence of heterotopic ossification(81). But Rofecoxib was 
withdrawn from the market by FDA because of concerns about increased risk of developing 
myocardial infarction and cerebrovascular accidents based on VIGOR study analysis(2,81,82).  
The basic understanding of theses NSAIDs mechanism of action is inhibition of prostaglandins 
thus causing decreased mesenchymal cell differentiation into osteoblastic cells. 
 
Bisphosphonates: 
Disodium etidronate is a bisphosphonate which may inhibit the mineralization of organic osteoid 
when used intravenously(83). It is used in the primary prevention of heterotopic ossification in 
the early phase and to decrease the amount of bone formation in late phases. If etidronate is 
initiated after bone scan evidence, but before heterotopic ossification findings in plain films, HO 
can be prevented(84). Experiments carried out on dogs by Peter CP et al suggests that 
bisphosphonates delay callus remodeling which impairs fracture healing(85). 
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Radiation therapy: 
Radiation prevents the differentiation of mesenchymal progenitor cells into heterotopic 
ossification forming osteoblasts(86). Radiation therapy given preoperatively is as effective as 
multi-fractionated post operative radiation therapy. In patients undergoing hip surgery radiation 
therapy prevents the formation of heterotopic ossification(87,88). However, a prospective 
randomized study by Hamid N et al showed increased risk of nonunion in elbow fractures when 
single- fraction therapy was administered(89). In a trial by Sautter-Bihl ML proved that there was 
no progression of heterotopic ossification but improvement in mobilization and rehabilitation 
when radiation therapy was administered following surgical resection of heterotopic 
ossification(90). 
 
Physiotherapy: 
Physiotherapy involves both active and passive ROM, gentle terminal stretch exercise and 
resisted ROM exercise. Though the aggressive exercises may increase the risk of HO formation, 
these exercises help in preventing movements and prevents ankylosis (91,92). 
 
Surgical management: 
Surgical resection of HO reduces pressure ulcers, impingement of important neurovascular 
structures and intractable pain and enhancing the function of mobility and giving care. Surgery is 
recommended one year following spinal cord injury(71). Alkaline phosphatase values, 
radiographs, 3D CT scan and bone scan data are to be considered before surgery. It is important 
to wait till maturity in order to minimize the recurrence rate following surgery. However 
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Freebourn TM et al suggest that resection of immature heterotopic ossification may not always 
have increased rate of recurrence(93). Delayed surgical intervention can lead to irreversible joint 
injury. The importance of timing for surgical intervention is to be investigated further. 
Recurrence is likely to be less in patients with good motor function and neurological recovery. In 
a case series by Moore TJ, patients who underwent surgical resection of heterotopic ossification 
and received concomitant bisphosphonate therapy, achieved 85° mean ROM for the hips and 65° 
mean ROM for the elbows(94). In another study,  Meiners T et al observed that 94.5° mean 
ROM was for the hip joints was achieved, if physiotherapy and concomitant radiotherapy were 
given during immediate post operative period and was sustained to a mean of 82.7° after 4 
years(95).  
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MATERIALS AND METHODS 
Study design 
Prospective, diagnostic pilot study in a spinal cord injury patients’ cohort group. 
Setting for the study 
The study was done in the Department of Physical Medicine and Rehabilitation (PM&R) of 
Christian Medical College Hospital (CMCH), Vellore. CMCH Vellore is a tertiary care centre 
located in Tamil Nadu, India. This centre has an inpatient capacity of about 2,700 beds. The 
number of patients attending OPD each day is approximately 5000.  The PM&R department of 
CMCH, Vellore has approximately 130 beds and its outpatient department serves around 100 
patients every day. Nearly 300 patients with spinal cord injury are rehabilitated in a year. Around 
20-40% of these admissions are diagnosed to have heterotopic ossification. 
This study was approved by the Institutional Review Board and Ethics committee of Christian 
Medical College and Hospital, Vellore. 
Participants  
Individuals with paraplegia and quadriplegia secondary to traumatic spinal cord injury classified 
as ASIA-A, ASIA-B, ASIA-C and ASIA-D from January 2013 to June 2014were involved in the 
study.  
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Inclusion criteria 
18-60yr old male and female patients after 3 weeks of spinal cord injury attending outpatient and 
inpatient sections of Department of Physical Medicine and Rehabilitation, Emergency 
Department and Department of  Spinal disorders of  Christian Medical College Hospital, Vellore 
were included in this study after informed consent. 
Exclusion criteria: 
a. Patients with recent history (one week) of medical/surgical conditions which tend to raise 
the serum levels of ALP or CPK such as rhabdomyolysis, muscular dystrophy, myoscitis, 
myocardial infarction, myocarditis, hypothyroidism, severe orthopedic trauma, disorders 
of bile duct obstruction, celiac disease, muscle hematomas, or organ tear were excluded 
from the study.  
b. Patients with existing ossification around hip joints/ bone pathology at the time of initial 
screening by pelvis X- ray were not included. 
c. Individuals who have had hip fracture after the recruitment which is radiologically 
proven were excluded from the study. 
d. Children and pregnant women were also excluded. 
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Selection of the study participants:  
X-ray imaging was done on all the participants to rule out any preexisting ossification around hip 
joints. Baseline CPK & ALP and Osteocalcin levels were not taken into consideration for the 
recruitment of participants. 
Sample size 
A total of 43 patients with acute spinal cord injury within 3 weeks of duration, were assessed for 
eligibility to include in the study.  30 patients were recruited for the study and only 16 subjects 
could finish the study. 
Methodology  
ALP, CPK and Osteocalcin were measured at around 3
rd
, 7
th
, 11
th
 and 16
th
 week of the injury. 
Osteocalcin samples are stored under -70°C to prevent the wastage of the reagent kit till the end 
of the study. Base line hip x-ray was checked for every patient at the time of recruitment.  All the 
blood samples were tested as per the standard operating procedures mentioned in the annexure. 
We interpreted the biomarker values as per the reference ranges established in CMCH Vellore 
Laboratory. The images of the reference standard i.e. Triple phase Technetium-99m bone scan 
were interpreted by nuclear medicine physician. The test results were not interpreted using 
clinical data from participants. 
Laboratory Tests Information 
CPK and ALP levels were measured using the Roche modular P800 analyzer with the respective 
reagents and N-mid osteocalcin by Roche modular E-170 analyzer. The Osteocalcin analyzer 
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was shown in Image no.1 and the reagent for osteocalcin which needs to be stored at 2-8°C 
which is shown in image no.2.  
 
Image 1: N- MID Osteocalcin analyzer -Rosche Modular E-170 
 
Image 2: N- MID Osteocalcin reagent. 
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CMCH, Vellore Normal ranges: 
ALP (adult)   :  40-125 U/L 
CPK Total Male  :  24-195U/L  
                   Female  :  25-170 U/L 
Osteocalcin by N-MID Elecsys Osteocalcin:  
Women premenopausal : < 31.2ng/mL 
Women postmenopausal : < 41.3ng/mL 
Men> 50yrs                    :  <26.3ng/mL 
Men <50yrs                             :             8-39ng/mL (with 2 SD; CMCH Vellore Laboratory) 
Depending up on the bone scan results the participants were divided in to two groups. They were 
1) Patients with HO and  
2) Patients without HO.  
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The methodology of the study is shown briefly in the figure no.1 
Figure 1. Methodology of the current study 
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RESULTS 
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RESULTS 
30 patients were screened with pelvis X-ray and recruited for the current study. There were 14 
drop outs during the 16 week follow up period and 16 completed the study with the 
establishment of the diagnosis by triple phase bone scan as shown in Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Flow chart depicting the participants of the study 
 
Pts with Spinal 
cord injury 
assessed for 
eligibility= 43 
          Pelvis X ray screen  
Recruited 
after 
informed 
consent =30 
Number of patients who completed the study 
with serial biomarker monitoring (N) =16 
Drop outs=14 
Diagnosis 
by bone 
scan 
 
 
HO 
group 
 
No HO 
group 
With inclusion criteria 
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Demography of the study participants 
Age group distribution 
 
Age in yrs 
 
Number of Patients with 
SCI 
 
Percentage 
 
18-20 
 
2 
 
12.50 
 
21-30 
 
9 
 
56.25 
 
31-40 
 
2 
 
12.50 
 
41-50 
 
1 
 
06.25 
 
51-60 
 
2 
 
12.50 
 
 
Total 
 
16 
 
100 
Table  4. Distribution of patients according to age group 
 
 
 
43 
  
Out of the 16 study patients 9 patients were from the age group of 21-30. This is consistent with 
most of the spinal cord injury incidence studies.  The mean of the ages of the participants is 32.6 
yrs.  
 
Figure 3.Distribution of patients according to age group 
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Gender distribution 
Gender      Number Percentage 
Males 15 94 
Female 1 6 
Table  5. Distribution of patients according to group 
Only one female patient was recruited in our study. This is in line with most of the studies 
showing less incidence of spinal cord injury in females. 
 
 Figure 4.Distribution of patients according to gender 
94% 
6% 
% of Gender distribution 
Male 
Female 
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Distribution according to mode of injury 
 
Mode of injury 
 
Number 
 
Percentage 
 
Fall  
 
11 
 
68.75 
 
RTA 
 
5 
 
31.25 
 RTA: Road traffic accidents 
Table 6. Distribution of patients according to mode of injury 
 
Figure 5.Distribution of patients according to mode of injury 
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Distribution according to completeness of the spinal cord injury 
 Number of patients Percentage 
Complete 11 68.75 
Incomplete 5 31.25 
Table  7. Distribution of patients according to complete/ incomplete 
 
 
Figure 6.Distribution of patients according to complete/ incomplete 
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Distribution according to type of management 
Management Number of patients Percentage 
Conservative 2 12.5 
Surgical 14 87.5 
Table 8.  Distribution of patients according to type of management 
 
Figure 7.Distribution of patients according to type of management 
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Distribution according to presence of HO 
 Number  Percentage 
HO 4 25 
No HO 12 75 
Total  16 100 
Table  9.  Distribution of patients according to presence of HO 
 
Figure 8. Percentage of SCI patients that developed HO 
25% 
75% 
% of HO 
HO 
Non HO 
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Individual biomarker levels in HO group patients during the initial 16weeks  
 
Figure 9. In HO group patients, the trend of CPK levels during the initial 16weeks showing 
heterogeneity.  X axis (weeks); Y axis- CPK levels in Units per litre. 
 
Figure 10. CPK patterns in the sera of four patients who developed HO. X axis (weeks); Y 
axis- CPK levels in Units per litre. 
CPK(3) CPK(7) CPK(11) CPK(16) 
Patient1 1708 190 212 130 
Patient2 1190 99 129 497 
Patient3 149 325 25 37 
Patient4 74 90 200 195 
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Figure 11.  In HO group patients, the trend of ALP levels during the initial 16weeks. X axis 
(weeks); Y axis- ALP levels in Units per litre. 
 
Figure 12. ALP patterns in the sera of four patients who developed HO. X axis (weeks); Y 
axis- ALP levels in Units per litre. 
ALP(3) ALP(7) ALP(11) ALP(16) 
Patient 1 167 115 126 108 
Patient 2 91 62 62 111 
Patient 3 344 112 521 329 
Patient 4 136 130 246 162 
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Figure 13. In HO group patients, the trend of osteocalcin  levels during the initial 16weeks. 
X axis (weeks); Y axis- Osteocalcin levels in nanograms per millilitre. 
 
Figure 14. Osteocalcin patterns in the sera of four patients who developed HO. X axis 
(weeks); Y axis- Osteocalcin levels in nanograms per millilitre. 
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Individual biomarker levels in non-HO group patients during the initial 16weeks 
 
 
 
Table 10.  CPK levels at different weeks in patients belonging to non-HO group 
 
 
 
S.No CPK(3) CPK(7) CPK(11) CPK(16) 
Patient 1 314 96 72 58 
Patient 2 990 95 93 160 
Patient 3 418 207 116 90 
Patient 4 179 79 124 92 
Patient 5 82 47 93 98 
Patient 6 390 71 70 85 
Patient 7 43 42 49 65 
Patient 8 352 117 78 74 
Patient 9 136 423 273 195 
Patient 10 304 446 226 119 
Patient 11 270 44 66 47 
Patient 12 228 40 52 36 
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Table  11.  ALP levels at different weeks in patients belonging to non-HO group 
 
 
 
S.No ALP(3) ALP(7) ALP(11) ALP(16) 
Patient 1 109 70 87 77 
Patient 2 133 111 95 84 
Patient 3 106 111 127 169 
Patient 4 98 77 89 77 
Patient 5 87 61 69 66 
Patient 6 212 79 85 94 
Patient 7 345 184 138 124 
Patient 8 155 134 127 113 
Patient 9 119 99 78 72 
Patient 10 156 110 106 107 
Patient 11 159 141 88 80 
Patient 12 184 93 79 116 
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Table  12.  Osteocalcin levels at different weeks in patients belonging to non-HO group 
 
 
 
S.No OsCal(3) OsCal(7) OsCal(11) OsCal(16) 
Patient 1 14 9 18 22 
Patient 2 10 25 21 - 
Patient 3 43 38 35 39 
Patient 4 18 13 21 22 
Patient 5 9 21 16 13 
Patient 6 11 24 31 28 
Patient 7 14 21 30 30 
Patient 8 18 28 27 32 
Patient 9 15 21 26 15 
Patient 10 26 22 37 44 
Patient 11 18 32 30 27 
Patient 12 6 18 17 13 
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 Figure 19. Active HO around bilateral hip joints & proximal femurs in bone 
scan at 16 weeks in patient no.1 
Figure 18. Initial pelvis X- ray of 
patient no.1 shows normal 
bilateral hip joints 
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Figure 20. Initial pelvis X- ray 
of patient no.2  shows normal 
bilateral hip joints 
Figure 21. Active HO in bilateral hip joints in bone scan at 16 weeks in 
patient no.2 
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Figure 22. Initial pelvis X- ray 
of patient no.3  shows normal 
bilateral hip joints 
Figure 23. HO in pelvis and right thigh in bone scan at 16 weeks in 
patient no.3 
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Figure 24. Initial pelvis X- ray 
of patient no.4  shows normal 
bilateral hip joints 
Figure 25. Active HO of left proximal femur in bone scan at 16 weeks in 
patient no.4 
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STATISTICAL ANALYSIS 
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Statistical Analysis 
The final results were compared and analyzed with two sided Fisher Exact test using SPSS 
software. We found there is no significant correlation of CPK values at different weeks with the 
later developing heterotopic ossification in the four patients and ALP values at different weeks 
showed there is no specific co relation with the HO that was noticed after 16weeks. 
CPK at 3weeks  
The range of CPK levels in HO patients at 3
rd
 week is between 74 and 1.708 U/L with mean 
value of 780U/L. The Sensitivity and specificity of the third week CPK is calculated from the 
following two way tables. The P value for CPK at 3
rd
 week in diagnosing HO is 0.547 which is 
not significant. 
CPK at 3
rd
 week HO No HO Total 
Positive 2 9 11 
Negative 2 3 5 
Total 4 12 16 
Sensitivity = 50%      Specificity = 25% PPV = 18.18%       NPV = 60% 
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CPK at 7 weeks  
The range of CPK levels in HO patients at 7
th
 week is between 90 and 325 U/L with mean value 
of 176U/L. The Sensitivity and specificity of the seventh week CPK is calculated from the 
following two way tables. The P value of CPK at 7
th
 week in diagnosing HO is 1.0 which is not 
significant. 
CPK at 7
th
  
week 
HO No HO Total 
Positive 1 3 4 
Negative 3 9 12 
Total 4 12 16 
Sensitivity = 25% Specificity =75 % 
PPV = 25% NPV = 75%  
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CPK at 11 weeks  
The range of CPK levels in HO patients at 11
th
 week is between 25 and 212 U/L with mean value 
of 142U/L. The Sensitivity and specificity of the eleventh week CPK is calculated from the 
following two way tables. The P value of CPK at 11
th
 week in diagnosing HO is 0.245 which is 
not significant. 
CPK at 11
th
  
week 
HO No HO Total 
Positive 2 2 4 
Negative 2 10 12 
Total 4 12 16 
Sensitivity =50 % Specificity =83.33% 
PPV = 50% NPV = 83.33% 
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CPK at 16 weeks  
The range of CPK levels in HO patients at 16
th
 week is between 37and 497 U/L with mean value 
of 215U/L. The Sensitivity and specificity of the sixteenth week CPK is calculated from the 
following two way tables. The P value of CPK at 16
th
 week in diagnosing HO is 0.250 which is 
not significant. 
CPK at 16
th
 
week 
HO No HO Total 
Positive 1 0 1 
Negative 3 12 15 
Total 4 12 16 
Sensitivity = 25% Specificity = 1% 
PPV = 1% NPV = 80% 
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ALP at 3 weeks  
The range of ALP levels in HO patients at 3
rd
 week is between 91 and 344 U/L with mean value 
of 185U/L. The Sensitivity and specificity of the third week ALP is calculated from the 
following two way tables. The P value of ALP at 3
rd
 week in diagnosing HO is 1.0 which is not 
significant. 
ALP at 3
rd
 week HO No HO Total 
Positive 3 8 11 
Negative 1 4 5 
Total 4 12 16 
Sensitivity = 75% Specificity = 33.33% 
PPV = 27.27% NPV = 80% 
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ALP at 7 weeks  
The range of ALP levels in HO patients at 7
th
 week is between 62 and 130 U/L with mean value 
of 105U/L. The Sensitivity and specificity of the seventh week ALP is calculated from the 
following two way tables. The P value of ALP at 7
th
 week in diagnosing HO is 1.0 which is not 
significant. 
ALP at 7
th
 week HO No HO Total 
Positive 1 3 4 
Negative 3 9 11 
Total 4 12 16 
Sensitivity = 25% Specificity = 75% 
PPV = 25% NPV = 75% 
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ALP at 11 weeks  
The range of ALP levels in HO patients at 11
th
 week is between 62 and 521 U/L with mean value 
of 239U/L. The Sensitivity and specificity of the eleventh week ALP is calculated from the 
following two way tables. The P value of ALP at 11
th
 week in diagnosing HO is 0.118 which is 
not significant. 
ALP at 11
th
 
week 
HO No HO Total 
Positive 3 3 6 
Negative 1 9 10 
Total 4 12 16 
Sensitivity = 75% Specificity = 75% 
PPV = 50% NPV = 90% 
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ALP at 16 weeks  
The range of ALP levels in HO patients at 16
th
 week is between 108 and 329U/L with mean 
value of 178U/L. The Sensitivity and specificity of the sixteenth week ALP is calculated from 
the following two way tables. The P value of ALP at 16
th
 week in diagnosing HO is 0.136 which 
is not significant. 
ALP at 16
th
 
week 
HO No HO Total 
Positive 2 1 3 
Negative 2 11 13 
Total 4 12 16 
Sensitivity = 50% Specificity = 91.66% 
PPV = 66,66% NPV = 84.61% 
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Osteocalcin at 3 weeks  
The range of Osteocalcin levels in HO patients at 3
rd
 week is between 8 and 50ng/dL with mean 
value of 22ng/dL. The Sensitivity and specificity of the third week osteocalcin is calculated from 
the following two way tables. The P value of Osteocalcin at 3rd week in diagnosing HO is 0.450 
which is not significant. 
Osteocalcin at 
3
rd
 week 
HO No HO Total 
Positive 1 1 2 
Negative 3 11 14 
Total 4 12 16 
Sensitivity = 25% Specificity = 91.66% 
PPV = 50% NPV = 78.57% 
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Osteocalcin at 7 weeks  
The range of Osteocalcin levels in HO patients at 7
th
 week is between 10 and 44ng/dL with mean 
value of 24ng/dL. The Sensitivity and specificity of the seventh week osteocalcin is calculated 
from the following two way tables. The P value of Osteocalcin at 7
th
 week in diagnosing HO is 
0.050. 
Osteocalcin at 
7
th
 week 
HO No HO Total 
Positive 2 0 2 
Negative 2 12 14 
Total 4 12 16 
Sensitivity = 50% Specificity = 100% 
PPV = 100% NPV = 85.71% 
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Osteocalcin at 11 weeks  
The range of Osteocalcin levels in HO patients at 11
th
 week is between 14 and 38ng/dL with 
mean value of 26ng/dL. The Sensitivity and specificity of the eleventh week osteocalcin is 
calculated from the following two way tables. The P value of Osteocalcin at 11
th
 week in 
diagnosing HO is 0.250 which is not significant. 
Osteocalcin at 
11
th
 week 
HO No HO Total 
Positive 1 0 1 
Negative 3 12 15 
Total 4 12 16 
Sensitivity = 25% Specificity = 100% 
PPV = 100% NPV = 80% 
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Osteocalcin at 16 weeks  
The range of Osteocalcin levels in HO patients at 16
th
 week is between 15 and 46ng/dL with 
mean value of 27ng/dL. The Sensitivity and specificity of the sixteenth week osteocalcin is 
calculated from the following two way tables. We were not able to measure the osteocalcin level 
at sixteenth week for one patient in the no HO group. The P value of Osteocalcin at 16
th
 week in 
diagnosing HO is 0.154 which is not significant. 
 
Osteocalcin at 
16
th
 week 
HO No HO Total 
Positive 2 1 3 
Negative 2 10 12 
Total 4 11 15 
Sensitivity = 50% Specificity = 90.9% 
PPV = 66.66% NPV = 83.33% 
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The Sensitivity, specificity, PPV and NPV of CPK levels at different weeks are as follows 
 CPK(3) CPK(7) CPK(11) CPK(16) 
Sensitivity 50 25 50 25 
Specificity 25 75 83.33 1 
PPV 18.18 25 50 1 
NPV 60 75 83.33 80 
Table 13.  Sensitivity, specificity, PPV and NPV of CPK levels at different weeks 
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The Sensitivity, specificity, PPV and NPV of ALP levels at different weeks are as follows 
Table 14.  Sensitivity, specificity, PPV and NPV of ALP levels at different weeks 
 
 
 ALP(3)% ALP (7)% ALP (11)% ALP (16)% 
Sensitivity 75 25 75 50 
Specificity 33.33 75 75 91.66 
PPV 27.27 25 50 66.66 
NPV 80 75 90 84.61 
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The Sensitivity, specificity, PPV and NPV of Osteocalcin levels at different weeks are as follows 
Table 15.  Sensitivity, specificity, PPV and NPV of Osteocalcin levels at different weeks 
 
 
 Osteocalcin(3)% Osteocalcin(7)% 
 P  Value- 0.050 
Osteocalcin(11)% 
P value-0.250 
Osteocalcin(16)% 
Sensitivity(%) 25 50 25 50 
Specificity 91.66 100 100 90.90 
PPV 50 50 100 66.66 
NPV 78.57 85.71 80 83.33 
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DISCUSSION 
The necessity of a test, which is low cost and quick yet reliable, for early diagnosis of HO and 
initiation of prompt treatment has been a biggest question since the description of the condition 
in the literature.  In this study we attempted to see the diagnostic value of various biochemical 
markers like CPK, ALP and Osteocalcin. 
Creatine phosphokinase: 
Identifying the role of CPK in diagnosis of later forming HO has been a greater challenge for 
researchers. In 2003, Singh et al observed the greater predictive value of CPK for subsequent HO 
formation compared to elevated ALP levels(22). They noticed a correlation between high levels 
of CPK and grades 2-4 of Brooker classification of HO. That initiated more focus on CPK as a 
potential tool in further studies. We, in our study attempted to see the behavior of CPK levels in 
patients that developed HO. As the peak period of HO is seen in early four months in spinal cord 
injury patients, we diagnosed the condition with the gold standard test, the triple phase bone scan 
at the end of study. Out of four patients who developed HO, two had increased levels of CPK 
levels at 3
rd
 week which is not statistically significant. Out of these two, only one patient had 
massive HO with ankylosis though HO grading and quantification were not done using the plain 
X-rays. Interestingly both these patients had normal levels of CPK after 1month duration. Hence 
checking the CPK levels might be still remaining as inconclusive and may not be useful indicator 
for the subsequent HO development. This could be conflicting with the previously published data 
with almost same numbers but with relatively more number of HO patients i.e. 7 vs. 4.  Few 
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unidentified conditions like muscle injury, subtle liver laceration which is asymptomatic and 
surgical handling of the muscle tissues can influence the levels of CPK. 
 
Alkaline phosphatase:  
ALP has been the test of choice for monitoring the growth of HO as this represents the 
osteoblastic activity. In the present study, we observed all the four subjects who developed HO 
had vertebral fracture and were all managed surgically. The rising trend of ALP in developing 
HO has been well described in the literature. We did not observe that pattern in our study in all 
the four patients who developed HO. Only one patient out of these had persistent elevated 
values. This could be due to the timing of maturity of HO which influences the ALP values. This 
particular point of time can only be identified through serial bone scans which are not 
economically feasible. As all these patients had fracture of vertebrae, commenting on the ALP 
elevation pattern may not be of much significance.  
 In the initial four months, the ALP levels are affected by the associated fractures and surgical 
intervention. Most of the patients with complete spinal cord injuries usually have concomitant 
limb bone fractures or at least vertebral fractures. Cassar Pullicino noticed the rising ALP trend, 
(though the values are still within normal limits) may be present in patients who are diagnosed 
with bone scan. But we could not see any rising trend as such in the patients with HO. Another 
pitfall of ALP is, minimal HO may not be evident. This we observed in one of four patients with 
HO in whom there is no single elevated ALP value observed. Hence one should not rely on 
serum ALP values especially during the first four months.  
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Osteocalcin:  
We failed to find any research work done in prediction of the HO in spinal cord injury patients. 
A study done in traumatic brain injury patients in 1993 showed osteocalcin as a poor adjunct to 
confirm the diagnosis and it did not show any maturation of the condition. The basic 
pathophysiology in HO in spinal cord injury patients and brain injury patients could be 
potentially different as it is obvious from one study that the fracture healing in brain injury is 
more than that of without associated brain injury(52). In our study, we noticed osteocalcin at 7
th
 
week could be a possible test to identify possibility of not developing HO if the test is normal. 
(Sensitivity is 100% and Negative predictive value NPV = 85.71%, P Value 0.050). But the 
actual significance should be checked with the larger sample sizes. Just like other biomarkers, 
Osteocalcin also has peculiar way of its presence in the blood. During the early phase of 
mineralization after fracture, osteocalcin levels will be high and as the mineralization continues 
the levels will reduce(96). Our study substantiates the earlier finding in brain injury patients, that 
it may not be a useful tool in diagnosis of the condition and cannot imply the maturity of the 
same.  
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Conclusions 
1. CPK may not be a good early biochemical marker for diagnosing the HO in 
spinal cord injury patients. The rising trend may not be observed in all 
patients who develop HO implying its poor quality to assess the HO 
maturity. 
2. ALP can be serially monitored to check the osteoblastic activity only in the 
context of absence of bone injury. Interpretation of ALP values in first four 
months of the injury should be done carefully. 
3. Osteocalcin in spinal cord injury patients is not a good tool in predicting the 
future developing HO. 
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LIMITATIONS OF THE STUDY 
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Limitations of the Study 
1. Sample size is small to conclude firmly on any of the biomarkers to predict the HO. The 
unequal distribution of the patients in both HO and No HO groups may be another 
confounding factor. 
2. The dropout rates are high in the current study. We noticed less enthusiasm of the 
participants as it is economically burden for most of them after a major incident of spinal 
cord injury.   
3. Clinical data especially range of hip joints were not accurately assessed at different 
intervals. Hence it was not analysed in the study which could have given valid functional 
information. 
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FURTHER RESEARCH 
RECOMMENDATIONS 
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Further Research Recommendations 
1. Influence of HO on functional activities of the spinal cord injury patient 
should be studied which can be treatment oriented. 
2. Large sample size to show any statistical significance of the biomarkers in 
identifying in the early stage or even before the onset of HO formation. 
3. Identifying the more HO specific bone morphogenic proteins and relevant 
new bone forming markers which are economically feasible. 
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                 This informed consent form is for the adult patients who sustained traumatic spinal 
cord injury (ages of 18 – 54yr) we have selected to participate in the research to see the 
effectiveness of various biomarkers to diagnose early the condition of new bone formation 
(heterotopic ossification). 
 
Name of Principle Investigator :  Dr. Vijay Kumar Manda 
                                                                     (Ph no. 09442681677, 0416-2282158) 
 
Name of Sponsors   :  IRB fluid grant and PM&R special fund 
 
Name of Project   :  Role of biomarkers in early detection of heterotopic  
      ossification following spinal cord injury. 
 
Expected duration of the subject’s : From 3rd week to 16th week after traumatic spinal 
participation      cord injury. 
 
Initial baseline blood investigations like serum creatine phosphokinase, osteocalcin, alkaline 
phosphatase and baseline X-ray of pelvis and same biomarkers at 7th, 11th and 16th week after 
injury along with bone scintigraphy at 16th week after injury to be taken for the confirmation of 
presence of disease. 
 
The subject will not be benefited from the study. However the study results will contribute to the 
upcoming research on the early prediction of heterotopic ossification, which can potentially 
affect the rehabilitation and thus arresting the further progression of the condition by appropriate 
intervention. 
 
Confidentiality:  
This study is strictly confidential; the information will not be seen by others. No one will have 
access to the forms except the project team. All the information about you that will be collected 
from the research will be put away and no-one but the researchers will be able to see it. Any 
information about you will have a number on it instead of your name.  
 
You can contact the principle investigator for any queries, rights of subjects and in the event of 
any injury
1
. 
 
Subject’s responsibilities on participation: To attend the PM&R OPD as per the requirement 
especially 7th, 11th and 16th week following the spinal cord injury for the collection of blood 
samples and bone scan at the end of the study(16th week). Your contact details (mobile/home 
landline number/e-mail address) will be taken to remind you about your next visit. The subjects 
are requested to arrange the transport expenses on their own. 
Christian Medical College, Vellore 
Tamil Nadu, India 
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The participation in this project is voluntary and the subject can withdraw from the study at any 
time. The refusal to participate will not involve any penalty or loss of benefits to which the 
Subject is otherwise entitled
2
.  
 
The principle investigator has the right to decide on the termination of the subject’s participation 
depending upon foreseeable circumstances without the subject’s consent. Approximate number 
of subjects enrolled in the study is 20. 
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                                                     Informed Consent form 
 
Study Title:  Role of biomarkers in early detection of heterotopic ossification following  
spinal cord injury 
 
Study Number: 
 
Subject’s Initials: _________ Subject’s Name: ________ 
 
Date of Birth / Age:_______ 
 
Please initial box  
 
(Subject) 
(i) I confirm that I have read and understood the information sheet dated _________ for 
the above study and have had the opportunity to ask questions. [  ] 
 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [ ] 
 
(iii) I understand that the Sponsor of the project, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to 
look at my health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. I agree to 
this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published. [  ] 
 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [  ] 
 
(v) I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject / 
Legally Acceptable Representative:    ___________________________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
Signature/thumb of the Investigator: _________________________ 
 
Study Investigator’s Name:  Dr. Vijay Kumar Manda (Ph no. 09442681677, 0416-2282158) 
Signature of the Witness (or Thumb impression): ___________Date:_____/_____/_______ 
 
Name of the Witness: ________________________________ 
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SOP’s for the automated chemistry analyser 
CREATINE KINASE (Creatine (phospho)kinase, CK or CPK )  EC 2.7.3.2. 
 
 
Test introduced: March 1985 
Review Date:  Annual 
Analyser:  Automated chemistry analysers 
Frequency:  available 24 hrs continuously 
Analysis time:  urgent results available within 90 mins 
 
Summary and explanation of the test 
 
UV, Kinetic, N-acetyl cysteine activated (NAC) for serum. 
This is an optimised standard method conforming to the recommendations of the Deutsche 
Gesellschalt for  Klinische Chemie.   NAC presents inactivation of CK.  The activity of CK is 
proportional to the rate of increase of absorbance due to NADPH production. 
  
Clinical Indications for the test 
 
CK is an isoenzyme consisting of 2 protein subunits M and B.  The predominant isoenzyme in 
brain is CK-BB and in muscle CK-MM.  CK converts energy stored in creatinine phosphate into 
ATP for use in situ.  CK raises 3-6 hrs after a myocardial infarct and returns to normal in 2-3 
days unless a second infarct occurs.  It is also increased after heavy exercise and in musclar 
dystrophies and trauma. 
 
Specimen type, collection and storage 
 
Serum or heparinised plasma may be used. EDTA plasma may cause unpredictable rates.   
Activity decrease in serum after 7 days at 4
0
C:  2% 
                24 hrs at 25
0
C: 2% 
Visible Haemolysis interferes in the test. 
 
Principle of the method 
 
The following is the series of reactions involved: 
 
              CK 
Creatine Phosphate + ADP ------------------> Creatine + ATP 
 
    HK  
Glucose + ATP --------------------------> G-6-P + ADP 
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 G-6-P-DH  
G-6-P + NADP
+
 -----------------------> 6-PG + NADPH  + H
+
 
 
The increase in absorbance at 340 nm, resulting from the formation of NADPH is proportional to 
the activity of Creatine Kinase in the sample. 
HK = hexokinase, G-6-P-DH = Glucose-6-phosphate dehydrogenase 
 
Source of the Method Protocol 
Manufacturers kit insert (Roche Diagnostics, GmbH) 
DIASYS Diagnostic systems Holzheim GmbH, 
 Randox , Crumlin, UK 
 
Rec. GSCC (DGKC)   J. Clin Chem Clin Biochem 1977; 15: 255. 
Szasz  G et al.   Clin Chem. 1976; 22:650. 
Stein W. Med. Welt 1985; 36: 572 
 
Hazardous Reagents 
 
Sodium azide: avoid contact with skin and mucous membranes.  Flush affected areas with 
copious amounts of water.  Seek medical attention for eyes or if ingested.   Sodium azide may 
react with lead or copper plumbing to form potentially explosive metal azides.   When disposing 
of, flush away with large quantities of water to prevent azide build up.  Clean exposed metal 
surfaces with 10% sodium hydroxide solution. 
 
Reagents 
ROCHE 
1.  reagent tablets (CK 1a ) containing coenzyme, substrate ( keep bottle tightly closed) 
2.  Imidazole buffer (CK 1) 
Preparation of reagents ROCHE 
Dissolve one reagent tablet in 15 ml of buffer as per the manufacturers instructions 
Reagent 1:  (R1)  
Contents     Concentration in the working solution 
Imidazole buffer   0.1 mol/L,   pH   6.7 
Glucose    20.0 mmol/L 
Mg2+     10.0 mmol/L 
EDTA     2.0 mmol/L 
HK     >  2.5 U/ml 
G6P-DH    >  1.5 U/ml 
ADP     2.0 mmol/L 
AMP     5.0 mmol/L 
Diadenosine pentaphosphate  10.0  mmol/L 
NADP     2.0 mmol/L 
Creatine phosphate   30.0 mmol/L   
N-acetyl cysteine   20.0 mmol/L 
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Reagent storage and stability 
Working reagent (R1) is stable for seven days at 2-8
0
C. 
                                                       12 hours at 15- 25
0
C. 
RANDOX  
Reagent 1:  (R1a) Buffer/glucose 
Contents     Concentration in the working solution 
Imidazole buffer   0.1 mol/L,   pH   6.7 
Glucose    20.0 mmol/L 
Magnesium Acetate    10.0 mmol/L 
EDTA sodium    2.0 mmol/L 
Stabilizers and preservatives, sodium azide  
Contents ready to use. Stable up to expiry date at 2-8 
0
C 
Reagent 1:  (R1b) Enzymes/Coenzymes/Substrate 
Contents     Concentration in the working solution 
ADP     2.0 mmol/L 
AMP     5.0 mmol/ 
Diadenosine pentaphosphate  10.0  mol/L 
NADP     2.0 mmol/L 
HK     >  2.5 U/ml 
G-6-P-DH    >  1.5 U/ml 
N-acetyl cysteine   20.0 mmol/L 
Creatine phosphate   30.0 mmol/L 
 
Reconstitute one vial of R1b with the appropriate volume of R1a. that is as instructed on the 
bottle 2.5 ml for a 2.5 ml bottle, 3.0 ml for a 3.0 ml bottle etc.  
  
Reagent storage and stability 
Working reagent (R1) is stable for 3 weeks at 2-8
0
C. 
                                                       3 days at 15- 25
0
C  
Standards 
Boehringer Mannheim (BM), GmbH, calibrator for automated systems (cfas), calibrator serum 
and solvent.  Made from the blood of donors individually tested and free from HbsAg, HCV1 
and antibody to HIV 1/2, and subjected to additional heat treatment.  Handle according to 
laboratory safety guidelines, as if potentially infectious. 
Calibration performed when quality controls exceed limits (see quality assurance file) 
 
Other required reagents 
 
Sodium chloride (0.9%) 
for preparation instructions, refer to the common reagent preparation folder 
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QC Interval 
 
Two different levels of commercial QC (from Boehringer Mannheim GmbH Precinorm U, 
BioRad  Laboratories Chemistry control and Randox, UK, human control serum level II or 
similar) are run twice  daily, in the morning and in the afternoon 
 
 
Quality control composition 
 
BM Precinorm U. Universal control serum.  Made from the blood of donors individually tested 
and free from HbsAg, HCV1 antibody to HIV, and subjected to additional heat treatment.  Other 
commercial QC material used is produced in a similar fashion.  Handle these QC‘s as if 
potentially infectious. 
 
External Quality Assessment schemes 
 
For details see quality assurance file 
 
Equipment/Instrumentation 
Method 
Parameters Roche Modular P800  RANDOX reagents 
Temperature    37C 
TEST Test number 013  [CK]  [  323 ] 
ASSAY CODE   [RATE A] [10]—[22]—[34]  
SAMPLE VOLUME (l) (N/DEC/INC)  [3.6—[ DF]—[DF] 
R1 VOLUME (l)    [180]—[0]—[0]  
R2 VOLUME (l)    [ 0 ]—[0]—[0] 
WAVELENGTH (nm)   [376—[340] 
CALIB. METHOD   [LINEAR] [2]—[2]—[0] 
STD. (1) CONC.-POS.   [0]—water [400] 
STD. (2) CONC.-POS.   [    ]  calibrator [401]  Rack position[S0001-2) 
UNIT     [U/L] 
SD LIMIT    [0.1] 
DUPLICATE LIMIT   [10]%  [500] Abs 
SENSITIVITY RANGE   [DF    ]—[DF   ]  DEFAULT (DF) 
ABS. LIMIT (INC)   [9000] 
PROZONE LIMIT   [32000]—[UPPER] 
TECHNICAL LIMIT   [0]—[2000] 
INSTRUMENT FACTOR                       [1.0] 
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Parameters Olympus ROCHE 
Parameter Specific 
Test No. 1  Test Name CK Sample Type  serum 
Sample Vol  5.0 Dil Vol  Min OD Max OD 
Reag 1 Vol  100 Dil Vol   L- 2.00 H+2.500 
Reag 2 Vol  25 Dil Vol  Linearity 15%  
Wave Main   340 Sub 410 Fst. L  Fst, H 
Method Rate   Slope +   
Point 1   Fst  21 Lst  27   Corrl factorA 1.000 
 
Parameters Olympus RANDOX 
Parameter Specific 
Test No. 1  Test Name CK Sample Type  serum 
Sample Vol  3.0 Dil Vol  Min OD Max OD 
Reag 1 Vol  150 Dil Vol   L- 2.00 H+2.500 
Reag 2 Vol  0 Dil Vol  Linearity 15%  
Wave Main   340 Sub 410 Fst. L  Fst, H 
Method Rate   Slope +   
Point 1   Fst  4 Lst  14   Corrl factorA 1.000 
 
 
 
Review of the results and quality control 
The senior person in charge of the analyser is responsible for ensuring that quality control values 
for all assays being run are acceptable.  Patient results may be released provided that the relevant 
QC’s are within their allowed limits. 
If QC’s are outside the limits, patient results cannot be reported.  Ascertain whether any error 
codes have occurred throughout the assay (refer to analyser SOP).   Rectify any problem 
according to SOP instructions and repeat analysis.  If there is a repeated failure of QC then call 
one of the senior staff. 
 
Manufacturers assay range: 2 -1940 U/L 
Dilution of high specimens 
If value exceeds 19400 U/L. dilute 1 in 10 with saline.  Dilute 100l of specimen with 900l 
of 0.9% saline and this figure can be multiplied 10.   If this value exceeds 2000 U/L further 
dilute this diluted specimen 1 in 10 and multiply the final figure x 100. 
 
Interference 
No significant effect of haemolysis/haemoglobin < 0.29g/dl 
Bilirubin up to 23.5 mg/dl or lipaemia/ triglycerides up to 550 mg/dl.  Visible haemolysis 
invalidates the assay. 
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Reporting of results 
Results reported to   nearest whole number 
Units    U/L 
Lower limit reporting range <10 U/L 
Phoning limits   not applied 
Reference Range  45—195 U/L 
 
 
Specimen storage and disposal 
Blood clots (primary specimen) are stored through the day at room temperature, kept for 3 
days at 4C and then discarded.    
All biological specimens are disposed of in accordance with the procedures described in the 
departmental health and safety manual  
 
Clinical Interpretation of results 
Pathological increases and decreases 
CK should be assayed 6 hours after the onset of chest pain is suspected myocardial 
infarction.  Infarction is confirmed by any two of ECG changes, chest pain, elevated CK ( 
twice upper reference limit) peak value occurs at 12-24 hrs with return to normal in 3 days. 
High levels of cardiac muscle origin:  Myocardial infarction, myocarditis . 
High levels of skeletal muscle origin:  Trauma, injection, muscular dystrophy and 
miscellaneous causes.  Low results are not significant. 
 
This SOP was reviewed by………………………………. 
 
and  approved by…………………………………………. 
 
Date…………………………………Number of copies in circulation…………………… 
 
 
This assay is only to be performed by staffs who have received training to operate the 
automated chemistry analysers and have read this SOP.   The list of these staff is held in the 
front of the automated chemistries laboratory procedures manual. 
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No amendment is to be made to this procedure unless agreed and approved by the persons 
named above, and then written into the procedural amendment form at the front of this 
manual. 
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SOP’s for Automated Chemistry analysers 
Alkaline Phosphatase  (ALP) EC 3.1.3.1 
 
Date of introduction: March 1995 
Review Date:  annual  
Analyser:  Automated Chemistry analysers 
Frequency:  daily, Monday to Saturday 
Analysis time:  results available the same working day, OP up to 1930 hrs 
 
Summary and explanation of the test 
 
Colorimetric, kinetic, p-nitrophenyl phosphate with AMP buffer. 
This is an optimised standard method confirming to the recommendation of the IFCC. The 
liberated phosphate group is transferred to water  and the reaction rate is enhanced by certain 
amino alcohol buffers such as   AMP ( 2 – amino – 2 methyl-1-propanol ) which act as a 
phosphate group acceptor. 
 
Clinical Indications for the test 
 
Phosphatases catalyse the splitting of phosphate group from monophosphoric esters, those 
operating at a alkaline pH optimum are called ALP.  ALP in the serum is a mixture of 
isoenzymes from liver, bone intestine and placenta, occurring particularly in osteoblasts (bone 
forming cells) and in the liver.  It is increased in bone disease associated with increased 
osteoblastic activity and in any form of biliary obstruction, which induces enzyme synthesis in 
hepatocytes adjacent to the biliary canaliculi.  It is a standard test for bone and liver disorders. 
 
Specimen type, collection and storage 
 
Serum is the preferred specimin but lithium heparin plasma is also suitable for this test. 
Stable for 7 days at 4
0
C                  0% activity decreased 
                7 days at 20-25
0
C          10% activity decreased 
 
Principle of the method 
The substrate is self indicating as the 4-nitrophenol is converted to 4-nitro phenoxide in alkali 
with increased in absorbance at 415 nm  being proportional  to the ALP activity. 
 
                    ALP 
p-nitrophenol phosphate   +   H20     ------------>        Phosphate + p –nitrophenol 
 
  
Source of the Method Protocol 
Tietz NW, Rinker D, Shaw LM. IFCC methods for the measurement of catalytic concentration of 
enzymes.  Part 5 IFCC method for alkaline phosphatase. J. Clin Chem Clin Biochem 1983; 21: 
731-748. 
Erba Manheim, TransAsia Biomedicals Ltd, Solan 
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Hazardous Reagents 
 
Hydrochloric acid: corrosive, toxic fumes, open concentrated solution only in fume cupboard. 
If solution comes in contact with skin or mucous membranes, flush immediately with large 
quantities of water.  If solution comes in contact with eyes, immediately flush liberally with 
water and consult an ophthalmologist 
Paranitrophenol : toxic, do not swallow or  inhale avoid contact with skin. 
 
Preparation of reagents 
 
All chemical used are “Analar grade”. 
Reagent1 (R1) :   AMP buffer, 0.35 mmol/L, pH 10.4 
In a 500 ml glass beaker add the following : 
Zinc sulphate heptahydrate   1.150g 
D/L Aspartic Acid, Magnesium salt tetrahydrate 2.88g 
EDTA (anhydrous acid)    2.34g 
To the above chemicals add 15mls of 6 M HCl and 400 ml of deionised water and mix well with 
a magnetic stirrer (the chemicals will not dissolve completely).  
In a 2L plastic beaker add 136 ml of  AMP  (free base)    
And  1 litre of  deionized  water. Add the above solution and mix. Now the chemicals will 
dissolve. 
Adjust the pH to 10.4 with approx 10ml of 6M Hcl. Finally make the solution up to 2 litres ibn a 
2 litre glass flask. 
    
Reagent  2 (R2) 
Dissolve 2.374g of p-nitrophenyl phosphate  in 200ml of the above reagent1 and mix well.   
Reagent storage and stability 
R1 stored in a brown bottle at 4
0
C, stable for 4weeks. 
R2 stable at 4
0
C for 4 weeks 
 
Erba Mannheim 
AMP buffer     350 mmol/L,  
Magnesium ions   2.0 mmol/L 
HEDTA     2.0 mmol/L 
 p-nitrophenyl phosphate    16.0 mmol/L 
Reagent preparation 
Reagents R1 and R2 are ready to use. Working reagent is prepared by mixing 4 parts of R1 with 
1 part of R2 reagent. 
Reagent stability 
Stable until expiry date when stored at 2 – 8 0C.   Working reagent is stable for 30 days at 2 – 8 
0
C 
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Standards 
 
Boehringer Mannheim (BM), GmbH, calibrator for automated systems (cfas), calibrator serum 
and solvent made from the blood of donors individually tested and free from HbsAg, HCV1 and 
antibody to HIV 1/2, and subjected to additional heat treatment.  Handle according to laboratory 
safety guidelines, as if potentially infectious. 
Calibration performed when quality controls exceed limits (see quality assurance file). 
 
Other required reagents 
Sodium chloride (0.9%) 
Hydrochloric acid 6 mol/L 
for preparation instructions, refer to the common reagent preparation folder 
 
QC Interval 
Two different levels of commercial quality control material (Boehringer Mannheim GmbH 
Precinorm U, BioRad chemistry control or Randox, UK, human control serum level II or 
similar), run twice daily, after instrument start up and each working afternoon. 
 
Quality control composition 
Commercial QC sera.  Made from the blood of donors and individually tested and free from 
HbsAg, HCV1 antibody to HIV, and subjected to additional heat treatment.  Other QC material 
made in a similar fashion.  Handle all QC’s as if potentially infectious. 
 
External Quality Assessment schemes 
 
For details see quality assurance file 
 
Equipment/Instrumentation 
Automated Chemistry analysers see instrument SOP’s for working instructions 
 
Parameters   Roche P800 (manual method) 
Temperature      37C 
TEST      [ALP]  [319] 
ASSAY CODE     [RATE - A] [8] — [13]—[19]  
SAMPLE VOLUME (l) SERUM (N/INC/DEC) [3 —[20] —[9] 
R1 VOLUME (l)     [60]—[60] 
R2 VOLUME (l)     [ 30]—[30] 
R3 VOLUME (l)     [ 0—[0] 
WAVELENGTH (nm) [2
ND
/PRI]   [480]—[415] 
CALIB. METHOD-LINEAR 2 POINT 2 SPAN  
STD. (1) CONC.-POS.    [0]—water [400] 
STD. (2) CONC.-POS.   [       ]—calibrator [401]  
UNIT     [U/L] 
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SD LIMIT    [0.1] 
DUPLICATE LIMIT   [10] % [ 500 ]Abs 
SENSITIVITY LIMIT   [      ]  ---- [         ]   DEFAULT 
ABS. LIMIT (INC)   [  2500  ] 
PROZONE LIMIT   [32000]—[UPPER]  
S1 ABS RANGE   [     ]—[        ] DEFAULT 
TECHNICAL LIMIT   [ -99999  ]—[2000    ]  
INSTRUMENT FACTOR  [1.0] 
 
Parameters Olympus 
Parameter Specific 
Test No. 6  Test Name ALP  Sample Type  serum 
Sample Vol  3.0 Dil Vol  Min OD  Max OD 
Reag 1 Vol  60 Dil Vol  60 L-  H+ 
Reag 2 Vol  60 Dil Vol   60   
Wave Main   410 Sub 480  Fst. L  Fst, H 
Method   Slope  +   
Point 1   Fst  13 Lst  19 Corrl factor  A 
 
 
Review of the results and quality control 
 
The senior person in charge of the analyser  is responsible for ensuring that quality control values 
for all  assays being run are acceptable.  Patient results may be released provided that the 
relevant QC’s are within their allowed limits. 
If QC’s are outside the limits, patient results cannot be reported.  Ascertain whether any error 
codes have occurred throughout the assay (refer to analyser  SOP).   Rectify any problem 
according to SOP instructions and repeat analysis.  If there is a repeated failure of QC then call 
one of the  senior staff. 
 
Manufacturers assay range  
 
5 – 1500 U/L 
 
Dilution of high specimens 
 
For values > 1500 U/L dilute 100 l specimen with 900l of saline and repeat the assay.  
Multiply the final result by a factor of 10. 
 
Interference  
 
Even very slightly haemolysed specimens are unsuitable. Haemolysis of 0.29g/dL of 
haemoglobin decreases values by 40%. 
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Reporting of results 
 
Results reported to   whole number 
Units    U/L 
Low reporting limit   <5 U/L 
Phoning limits   not applicable 
Reference Range  40  – 125 U/L adults 
 
 
Specimen storage and disposal 
 
Blood clots (primary specimen) are stored through the day at room temperature, kept for 3 days 
at 4C and then discarded.    
All biological specimens are disposed of in accordance with the procedures described in the 
departmental health and safety manual  
Clinical Interpretation of results 
Pathological increases and decreases 
Reference range for boys  up to 13-15  years is up to 362 U/L) and girls 10-12 years up to 332 
U/L  
In liver disease if ALP is  increased < 3 fold  there is predominantly hepatocellular damage.  
If  values of ALP > 3 X  increased there is predominantly cholestasis.   
High ALP due to heptobiliary disease is caused by cirrhosis, hepatic tumours, other space 
occupying lesions, cholangitis, extrabiliary obstruction. Liver disease is confirmed by 
abnormalities of other liver function tests. 
In bone disease, increase in ALP is due to Pagets disease, renal osteodystrophy, rickets, 
osteomalacia, hyperparathyrodisim, bone tumour, osteomyelitis. 
Low levels of ALP are uncommon and rarely of any consequence. 
  
 
This SOP was reviewed by………………………………. 
 
and approved by…………………………………………. 
 
Date………………………………………………………. 
 
Number of copies in circulation………………………….. 
 
This assay is only to be performed by staff who have received training to operate the chemistry 
analysers have read this SOP, and the manufacturers kit insert   The list of these staff is held in 
the front of the automated chemistries   laboratory procedures manual. 
No amendment is to be made to this procedure unless agreed and approved by the persons named 
above, and then written into the procedural amendment form at the front of this manual  
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N-MID Osteocalcin 
Intended use 
Immunoassay for the in vitro quantitative determination of N-MID osteocalcin in human serum 
and plasma. The determination is used for the control of antiresorptives therapeutic efficiency, 
e.g. for patients with osteoporosis or hypercalcemia. 
The electrochemiluminescence immunoassay “ECLIA” is intended for use on the Roche Elecsys 
1010 and 2010 immunoassay analyzers. 
 
Summary*
1–10
 
Osteocalcin, the most important non-collagen protein in bone matrix, is a bone-specific, 
calcium-binding protein which is dependent on vitamin K. It contains 49 amino acids and has a 
molecular weight of approx 5800 D. It contains up to three Ö-carboxyglutamic acid residues 
(bone-GLA-protein, BGP). 
During bone synthesis osteocalcin is produced by the osteoblasts. Its production is dependent 
upon vitamin K (formation of Ö-carboxyglutamic acid residues) and is stimulated by vitamin D3. 
After release from the osteoblasts, osteocalcin is not only assimilated into the bone matrix but 
also secreted into the blood stream. Accordingly, the serum (or plasma) osteocalcin level is 
related to the rate of bone turnover in various disorders of bone metabolism, e.g. osteoporosis in 
particular, but also in primary and secondary hyperparathyroidism or Paget's disease. 
Osteocalcin is therefore termed a bone turnover marker and is used for this purpose. By means 
of osteocalcin measurements it is possible to monitor therapy with antiresorptive agents 
(bisphosphonates or hormone replacement therapy, HRT) in, for example, patients with 
osteoporosis or hypercalcemia. 
Both intact osteocalcin (amino acids 1–49) and the large N-Mid fragment (amino acids 1–43) 
occur in blood. Intact osteocalcin is unstable due to protease cleavage between amino acids 43 
and 44 . The N-Mid-fragment resulting from cleavage is considerably more stable. 
The Elecsys N-MID Osteocalcin assay uses two monoclonal antibodies specifically directed 
against epitopes on the N-Mid-fragment and the N-terminal fragment. The test is non-dependent 
on the unstable C-terminal fragment (amino acids 43-49) of the osteocalcin molecule and thus 
ensures constant measurement results under routine conditions in the laboratory. 
 
**Tris(2,2’-bipyridyl)ruthenium(II) complex (Ru(bpy){) 
 
Test principle* 
Sandwich principle. Total duration of assay: 18 minutes 
 1st incubation: 20 µl of sample, a biotinylated monoclonal N-MID osteo-calcin-specific 
antibody and a monoclonal N-MID osteocalcin- specific antibody labeled with a 
ruthenium complex** react to form a sandwich complex.  
 2nd incubation: after the addition of streptavidin-coated microparticles, the complex 
becomes bound to the solid phase via interaction of biotin and streptavidin.  
 The reaction mixture is aspirated into the measuring cell where the microparticles are 
magnetically captured onto the surface of the electrode. Unbound substances are then 
removed with ProCell. Application of a voltage to the electrode then induces chemilumin-
escent emission which is measured by a photomultiplier.  
 Results are determined via a calibration curve which is instrument-specifically generated 
by 2-point calibration and a master curve pro-vided via the reagent bar code.  
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Reagents - contents and concentrations* 
Elecsys N-MID Osteocalcin reagent kit, Cat. No. 2149133 - 100 tests  
M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 ml: 
Streptavidin-coated microparticles, 0.72 mg/ml, binding capacity: 470 ng biotin/mg 
microparticles; preservative. 
R1 Anti-N-MID Osteocalcin Ab~biotin (gray cap), 1 bottle, 10 ml:  
      Biotinylated monoclonal anti-N-MID Osteocalcin antibodies (mouse)  
      1.5 mg/l; phosphate buffer 100 mmol/l, pH 6.0; preservative. 
R2 Anti-N-MID Osteocalcin Ab~Ru(bpy){ (black cap), 1 bottle, 10 ml:  
      Monoclonal anti-N-MID Osteocalcin antibodies (mouse) labeled with  
      ruthenium complex 1.3 mg/l; phosphate buffer 100 mmol/l, pH 6.0;  
      preservative. 
 
Precautions and warnings 
For in vitro diagnostic use, exercise the normal precautions required for handling all laboratory 
reagents. 
 
Reagent handling* 
The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated. 
All information required for correct operation is read in automatically via the reagent bar code. 
 
Storage and stability* 
Store at 2–8°C. 
Store the Elecsys N-MID Osteocalcin reagent kit upright in order to ensure complete availability 
of the microparticles during the automatic mixing prior to use.  
Stability:  
Unopened at 2–8°C after opening up to the stated expiration date twelve weeks at 2–8°C 
After opening  twelve weeks at 2-8°C 
On the Elecsys 2010  eight weeks 
On the Elecsys 1010  eight weeks (stored alternately in the refrigerator and on the 
analyzer – ambient temperature 20-25°C; upto 20 hours opened in total) 
 
Specimen collection and preparation* 
Serum collected using standard sampling tubes.  
Li-heparin treated plasma and K3-EDTA treated plasma. 
 
Note: Avoid haemolysis! Erythrocytes contain proteases which degrade osteocalcin. It is 
recommended that blood be centrifuged immediately. Stability of serum and heparinized plasma: 
8 hours at 15–25°C, three days at 2–8°C, 3 months at –20°C. Freeze only once.11 
Stability of EDTA-plasma: 2 days at 15–25°C, 3 days at 2–8°C, 3 months at –20°C. Freeze only 
once.
11
 
Samples containing precipitates must be centrifuged before performing the assay. Samples and 
controls stabilized with azide cannot be used. 
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Elecsys N-MID Osteocalcin testing procedure* 
Materials provided 
 
Cat. No. 2149133, Elecsys N-MID Osteocalcin reagent kit for 100 tests contains: 
• M   Streptavidin-coated microparticles  
• R1   Anti-N-MID Osteocalcin Ab~biotin  
• R2   Anti-N-MID Osteocalcin Ab~Ru(bpy){  
Materials required (but not provided)  
• Cat. No. 1972111, Elecsys N-MID Osteocalcin CalSet, for 10 calibra-tions  
• Cat. No. 1972227, PreciControl Bone, for 2 x 2 ml each of PreciControl Bone 1, 2 and 3  
• Cat. No. 1732277, Elecsys Diluent Universal, 2 x 18 ml sample diluent  
• Elecsys 1010 or 2010 analyzer  
• Cat. No. 1662988, Elecsys ProCell, 6 x 380 ml system buffer  
• Cat. No. 1662970, Elecsys CleanCell, 6 x 380 ml measuring cell cleaning solution  
• Cat. No. 1706829, Elecsys 1010 Assay Cup, 12 x 32 reaction vessels, or  
Cat. No. 1706802, Elecsys 2010 Assay Cup, 60 x 60 reaction vessels  
• Cat. No. 1706799, Elecsys 2010 Assay Tip, 30 x 120 pipette tips  
• General laboratory equipment  
Only available in the USA: 
• Cat. No. 2144093, Elecsys N-MID Osteocalcin CalCheck, for 3 levels. 
 
Assay* 
For optimal performance of the assay it is important to follow the dir-ections given for the 
analyzer used, and to check that the system’s inventory of assay materials and other 
consumables is adequate. 
Resuspension of the microparticles before use and the reading in of the test-specific parameters 
via the reagent bar code take place auto-matically. No manual input is necessary. If in 
exceptional cases the bar code cannot be read, enter the 15-digit sequence of numbers. 
 
Elecsys 2010: Bring the cooled reagents to approx. 20°C and place on the reagent disk of the 
analyzer. Avoid the formation of foam. The system automatically regulates the temperature of 
the reagents and the opening/closing of the bottles. 
 
Elecsys 1010: Bring the cooled reagents to approx. 20–25°C and place on the sample/reagent 
disk of the analyzer (ambient temperature 20– 25°C). Avoid the formation of foam. Open bottle 
caps manually before use and close manually after use. 
 
 
Calibrators* 
Elecsys N-MID Osteocalcin was calibrated against in-house reference standards: osteocalcin in 
analyte-free human serum matrix.
11
 
Every N-MID Osteocalcin reagent set has a bar-coded label containing the specific information 
for calibration of the particular reagent lot. The predefined master curve is adapted to the 
analyzer by the use of Elecsys 
N-MID Osteocalcin CalSet. 
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Calibration frequency: Calibration must be performed once per reagent lot using fresh reagent 
(i.e. not more than 24 hours since the reagent pack was registered on the analyzer). Renewed 
calibration is recommended as follows: 
Elecsys 2010: 
 after one month (when using the same reagent lot)  
 after seven days (when using the same reagent kit on the analyzer)  
Elecsys 1010:  
 with every reagent kit  
 after seven days (ambient temperature 20–25°C)  
 after three days (ambient temperature 25–32°C)  
Both analyzers: 
 as required: e.g. quality control findings outside the specified range. Calibration 
verification: Not necessary. The analyzer’s software auto-matically checks the validity of 
the curve and draws attention to any deviations. 
 
Quality control* 
Elecsys PreciControl Bone 1, 2 and 3 and other suitable controls. Controls for the various 
concentration ranges should be run as single de-terminations at least once every 24 hours when 
the test is in use and after every calibration. The control intervals should be adapted to each lab-
oratory’s individual requirements. Values obtained should fall within the defined ranges. Each 
laboratory should establish guidelines for corrective measures to be taken if values fall outside 
the range. 
 
Calculation* 
Elecsys 1010 and 2010 automatically calculate the N-MID osteocalcin concentration of each 
sample. 
The results are given in ng/ml. 
Limitations – interference*11 
The assay is unaffected by icterus (bilirubin < 65 mg/dl), lipemia (Intralipid < 1500 mg/dl) and 
biotin < 100 ng/ml (criterion: recovery within ± 10% of initial value). 
Hemolysis interferes. Erythrocytes contain proteases which degrade osteocalcin. In patients 
receiving therapy with high biotin doses (> 5 mg/day) no sample should be taken until at least 8 
hours after the last biotin admin-istration.
11
 
No influence was observed from rheumatoid factor up to 2200 U/ml. There is no high-dose hook 
effect at N-MID osteocalcin concentrations up to 4200 ng/ml. 
In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the 
assay was found. 
As with all tests containing monoclonal mouse antibodies, erroneous findings may be obtained 
from samples taken from patients who have been treated with monoclonal mouse antibodies or 
have received them for diagnostic purposes. Elecsys N-MID Osteocalcin contains additives 
which minimize these effects. In rare cases, interference due to extremely high titers of 
antibodies to streptavidin can occur. 
For diagnostic purposes, the Elecsys N-MID Osteocalcin findings should always be assessed in 
conjunction with the patient’s medical history, clinical examination and other findings. 
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Measuring (reportable) range*
11
 
0.500–300 ng/ml (defined by the lower detection limit and the maximum of the master curve). 
Values below the detection limit are reported as < 0.500 ng/ml. Values above the measuring 
range are reported as > 300 ng/ml (or up to 1500 ng/ml for 5-fold diluted samples). 
 
Dilution 
Samples having N-MID osteocalcin concentrations above the measuring range can be diluted 
with Diluent Universal. The recommended dilution is 1:5 (either automatically by the Elecsys 
1010/2010 or manually). The concentration of the diluted sample must be > 60 ng/ml. After 
manual dilution, multiply the result by the dilution factor. After dilution by the analyzers, the 
Elecsys 1010/2010 software takes the dilution into account when calculating the sample 
concentration. 
 
Expected values*
11
 
The expected values range is dependent on the assay type. Until completion of clinical studies 
with N-MID Elecsys Osteocalcin, the following provisional Enzymun-Test N-MID Osteocalcin 
results given below are valid (values correspond to the 95
th
 percentile in ng/ml). Lar-ger values 
are expected when using the Elecsys assay: 
 
 
 Number 
N-MID     
osteocalcin 
Women, premenopausal 200 31.2 
Women, postmenopausal, no HRT 211 41.3 
Men, ≥ 50 years 162 26.3 
 
 
Each laboratory should investigate the transferability of the expected values to its own patient 
population and if necessary determine its own reference ranges. 
Specific performance data of the test*
11
 
Precision 
Representative performance data on the Elecsys analyzers are given below. The results obtained 
in individual laboratories may differ. Reproducibility was determined using Elecsys reagents, 
pooled human sera and controls in a modified protocol (EP5-T) of the NCCLS (National 
Committee for Clinical Laboratory Standards): six times daily for ten days (n = 60). The 
following results were obtained: 
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  Intra-assay precision Total precision 
Sample Mean SD %CV SD %CV 
 ng/ml ng/ml  ng/ml  
Human serum 1 15.5 0.61 4.0 1.01 6.5 
Human serum 2 13.7 0.45 3.3 0.53 3.8 
Human serum 3 68.3 0.92 1.4 1.22 1.8 
PreciControl Bone 1 21.9 0.54 2.5 0.76 3.5 
PreciControl Bone 2 105.7 1.32 1.2 1.85 1.7 
PreciControl Bone 3 205.5 2.45 1.2 3.54 1.7 
 
 
Analytical sensitivity (lower detection limit) 
< 0.50 ng/ml 
The detection limit represents the lowest N-MID osteocalcin concen-tration that can be 
distinguished from zero. It is calculated as the concen-tration lying two standard deviations 
above that of the lowest standard (master calibrator, standard 1 + 2 SD, intra-assay precision, n 
= 21). 
 
Analytical specificity 
For the monoclonal antibodies used, the following cross-reactivities were determined: 
No cross-reactivity detectable for Ä-CrossLaps, parathyroid hormone or bone-specific alkaline 
phosphatase. 
 
Method comparison 
A comparison of Elecsys N-MID Osteocalcin (y) with a commercially available N-MID 
osteocalcin test (x) using clinical samples gave the following correlations (ng/ml): 
Number of samples measured: 185 
Passing/Bablok
12-14
 Linear regression 
y = -2.79 + 1.29x y = -6.24 + 1.43x 
r = 0.987 r = 0.987 
SD (md68) = 1.54 Sy.x = 3.28 
The sample concentrations were between approx. 10 and 210 ng/ml (x). 
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